E-resources
Peer reviewed
-
de Valence, Benjamin; Delaune, Marion; Nguyen, Yann; Jachiet, Vincent; Heiblig, Mael; Jean, Alexis; Riescher Tuczkiewicz, Stanislas; Henneton, Pierrick; Guilpain, Philippe; Schleinitz, Nicolas; Le Guenno, Guillaume; Lobbes, Hervé; Lacombe, Valentin; Ardois, Samuel; Lazaro, Estibaliz; Langlois, Vincent; Outh, Roderau; Vinit, Julien; Martellosio, Jean-Philippe; Decker, Paul; Moulinet, Thomas; Dieudonné, Yannick; Bigot, Adrien; Terriou, Louis; Vlakos, Alexandre; de Maleprade, Baptiste; Denis, Guillaume; Broner, Jonathan; Kostine, Marie; Humbert, Sebastien; Lifermann, Francois; Samson, Maxime; Pechuzal, Susann; Aouba, Achille; Kosmider, Olivier; Dion, Jeremie; Grosleron, Sylvie; Bourguiba, Rim; Terrier, Benjamin; Georgin-Lavialle, Sophie; Fain, Olivier; Mekinian, Arsène; Morgand, Marjolaine; Comont, Thibault; Hadjadj, Jerome
Annals of the rheumatic diseases, 03/2024, Volume: 83, Issue: 3Journal Article
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors. Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models. Seventy-four patients with 133 serious infections were included. The most common sites of infection were lung (59%), skin (10%) and urinary tract (9%). Microbiological confirmation was obtained in 76%: 52% bacterial, 30% viral, 15% fungal and 3% mycobacterial. Among the pulmonary infections, the main pathogens were 2 (28%), (21%) and (19%). Sixteen per cent of severe infections occurred without any immunosuppressive treatment and with a daily glucocorticoid dose ≤10 mg. In multivariate analysis, age >75 years (HR (95% CI) 1.81 (1.02 to 3.24)), mutation (2.29 (1.10 to 5.10)) and arthralgia (2.14 (1.18 to 3.52)) were associated with the risk of serious infections. JAK inhibitors were most associated with serious infections (3.84 (1.89 to 7.81)) compared with biologics and azacitidine. After a median follow-up of 4.4 (2.5-7.7) years, 27 (36%) patients died, including 15 (56%) due to serious infections. VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the mutation and treated with JAK inhibitors. The high frequency of atypical infections, especially in patients without treatment, may indicate an intrinsic immunodeficiency.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.